Back to Home
    Research & Industry

    2027 ASCO Genitourinary Cancers Symposium: What's Coming to San Francisco

    By RegenMed Review Editorial Team · Medically Reviewed by the RegenMed Review Editorial Team
    November 7, 20264 min read
    2027 ASCO Genitourinary Cancers Symposium: What's Coming to San Francisco

    What this article covers

    What This Article Covers
    In February 2027, oncologists, urologists, radiation specialists, and researchers will gather in San Francisco for the ASCO Genitourinary Cancers Symposium — the field's premier annual meeting on prostate, bladder, kidney, and other urologic cancers. This article covers what the meeting is, when and where it's happening, why it matters to patients and families tracking advances in cancer immunotherapy, and what recent years at this symposium suggest about where the science is heading.
    The Basics: Dates, Location, and Sponsors
    The 2027 ASCO Genitourinary (GU) Cancers Symposium is scheduled for February 11–13, 2027, at Moscone West in San Francisco, California, with both in-person and digital attendance options. The meeting is jointly sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) — a tri-society structure that reflects how genitourinary cancer care actually works in practice, bringing medical oncology, radiation oncology, and surgical urology together under one roof rather than treating them as separate conversations.
    Why This Meeting Matters for Immunotherapy Watchers
    GU cancers — particularly bladder (urothelial) and kidney (renal cell) cancer — have become some of the most active proving grounds for cancer immunotherapy outside of melanoma and lung cancer. Checkpoint inhibitors (drugs targeting PD-1/PD-L1) are now embedded in standard treatment for metastatic bladder and kidney cancer, and the open questions driving current research are about sequencing, combinations, and which patients benefit most — exactly the kind of practice-changing data this symposium is built to surface.
    What Recent Years Suggest Is on the Horizon
    The 2027 scientific program had not yet been published at the time of writing, but recent GU symposia point to several threads likely to continue:
    What to Watch For as the Meeting Approaches
    Patients, caregivers, and clinicians who want to follow along don't need to attend in person. ASCO typically releases a program guide and selected late-breaking abstracts in the weeks before the symposium, and major oncology outlets provide same-day coverage of practice-changing presentations.

    What This Article Covers

    In February 2027, oncologists, urologists, radiation specialists, and researchers will gather in San Francisco for the ASCO Genitourinary Cancers Symposium — the field's premier annual meeting on prostate, bladder, kidney, and other urologic cancers. This article covers what the meeting is, when and where it's happening, why it matters to patients and families tracking advances in cancer immunotherapy, and what recent years at this symposium suggest about where the science is heading.

    The Basics: Dates, Location, and Sponsors

    The 2027 ASCO Genitourinary (GU) Cancers Symposium is scheduled for February 11–13, 2027, at Moscone West in San Francisco, California, with both in-person and digital attendance options. The meeting is jointly sponsored by the American Society of Clinical Oncology (ASCO), the American Society for Radiation Oncology (ASTRO), and the Society of Urologic Oncology (SUO) — a tri-society structure that reflects how genitourinary cancer care actually works in practice, bringing medical oncology, radiation oncology, and surgical urology together under one roof rather than treating them as separate conversations.

    Why This Meeting Matters for Immunotherapy Watchers

    GU cancers — particularly bladder (urothelial) and kidney (renal cell) cancer — have become some of the most active proving grounds for cancer immunotherapy outside of melanoma and lung cancer. Checkpoint inhibitors (drugs targeting PD-1/PD-L1) are now embedded in standard treatment for metastatic bladder and kidney cancer, and the open questions driving current research are about sequencing, combinations, and which patients benefit most — exactly the kind of practice-changing data this symposium is built to surface. Readers following CAR-T, bispecific antibodies, or cell-based approaches more broadly in solid tumors will find GU cancers a useful bellwether, since bladder cancer in particular has become a test bed for combining antibody-drug conjugates (ADCs) with immunotherapy.

    What Recent Years Suggest Is on the Horizon

    The 2027 scientific program had not yet been published at the time of writing, but recent GU symposia point to several threads likely to continue:

    • Intravesical oncolytic immunotherapy for bladder cancer. At the 2026 meeting, a phase 3 trial of an oncolytic (virus-based) immunotherapy delivered directly into the bladder reported a roughly 75% complete response rate in a hard-to-treat, BCG-unresponsive patient group — an approach distinct from systemic checkpoint inhibition.
    • ADC-plus-checkpoint-inhibitor combinations. Pairing antibody-drug conjugates with PD-1/PD-L1 blockade continues to be tested across bladder and kidney cancer as a way to deepen and extend responses.
    • Perioperative and bladder-sparing immunotherapy strategies. Trials using checkpoint inhibitors before or after surgery — including some aimed at helping select patients avoid cystectomy altogether — have been a recurring theme.
    • Gut microbiome modulation as an immunotherapy adjunct. Early-phase kidney cancer trials have explored whether specific probiotic strains can improve response to checkpoint inhibitor combinations, an active but still exploratory area.

    None of this is confirmation of what the 2027 program will include — abstracts for the meeting are typically released only weeks beforehand — but it illustrates the kind of incremental, hard-won progress that defines this corner of oncology: not single breakthroughs, but a steady accumulation of combination strategies and patient-selection tools.

    What to Watch For as the Meeting Approaches

    Patients, caregivers, and clinicians who want to follow along don't need to attend in person. ASCO typically releases a program guide and selected late-breaking abstracts in the weeks before the symposium, and major oncology outlets provide same-day coverage of practice-changing presentations. As with any conference news, it's worth remembering that a notable result presented at a symposium is not the same as an FDA-approved treatment — trial data presented here often represents an early or intermediate step, and results can change as follow-up data mature or as regulators weigh in.

    Bottom Line

    The 2027 ASCO GU Cancers Symposium (February 11–13, Moscone West, San Francisco) is one of the most important annual checkpoints for tracking how cancer immunotherapy is evolving in bladder, kidney, and prostate cancer. While the specific 2027 agenda wasn't yet public at the time of writing, the trajectory from recent years — oncolytic immunotherapy, ADC-immunotherapy combinations, and bladder-sparing strategies — gives a reasonable preview of what's likely to be discussed. As always, readers should treat symposium presentations as a window into active research, not as evidence of an approved or widely available treatment, and should look for peer-reviewed publication and FDA review as the data matures.

    Key Questions Answered

    When and where is the 2027 ASCO GU Cancers Symposium?
    February 11–13, 2027, at Moscone West in San Francisco, with both in-person and digital attendance options.
    What immunotherapy research might feature at the meeting?
    Recent meetings suggest oncolytic bladder immunotherapy, ADC-checkpoint inhibitor combinations and bladder-sparing strategies may remain active themes. The 2027 program was not yet public at the time of writing.
    Does a symposium result mean a treatment is approved?
    No. Conference presentations are a window into research, not evidence of FDA approval or widespread availability. Peer-reviewed publication, mature follow-up and regulatory review still matter.

    Sources

    • 2027 American Society of Clinical Oncology Genitourinary (ASCO GU) Cancers Symposium, UroToday, 2026, https://www.urotoday.com/calendar-events/2027-american-society-of-clinical-oncology-genitourinary-asco-gu-cancers-symposium.html
    • American Society of Clinical Oncology GU Cancers Symposium 2027, Moscone Center, 2026, https://moscone.com/events/american-society-clinical-oncology-gu-cancers-symposium-2027
    • ASCO GU 2026 Deep Dive: Practice-Changing Data From the Genitourinary Cancers Symposium, MDLinx, 2026, https://www.mdlinx.com/article/asco-gu-2026-deep-dive-practice-changing-data-from-the-genitourinary-cancers-symposium/1fnPo5aF6LdEKfnObdnqHM
    • ASCO Daily News Podcast, American Society of Clinical Oncology, https://podcasts.apple.com/al/channel/asco-podcasts/id6443252142

    Related Articles

    The Review Dispatch

    Our weekly briefing on the regenerative medicine landscape, for researchers, clinicians, and investors.

    regenmedreview

    regenmedreview is an independent reference library covering stem cell therapy and cancer immunotherapy research — compiled for researchers, clinicians, and patients exploring the field.

    The information on this site is for general educational purposes only and does not constitute medical advice. Regenerative medicine treatments discussed here may not be approved or available in all jurisdictions. Always consult a licensed physician before making treatment decisions.

    © 2026 regenmedreview. All rights reserved.Independent. Unaffiliated. Reader-supported.